Related Experiment Videos
[Prevention of cardiovascular diseases in elderly subjects with hypercholesterolemia]
1Service d'Endocrinologie-Métabolisme, Unités de Prévention des Maladies Cardiovasculaires, Hôpital Pitié Salpétrière, 83 boulevard de l'Hôpital, 75013 Paris, France.
Insights
Managing hyperlipidaemia in elderly patients with cardiovascular disease requires a personalized approach due to unique health profiles and limited specific studies. Statins show promise, but treatment decisions consider individual risk and life expectancy.
Area of Science:
- Gerontology
- Cardiology
- Pharmacology
Context:
- Cardiovascular diseases (CVD) and hyperlipidaemia are prevalent in the elderly.
- Elderly patients present unique characteristics, including a higher proportion of women and increased cerebrovascular accident incidence.
- Limited specific therapeutic studies in the elderly necessitate a case-by-case management strategy.
Purpose:
- To review the challenges and considerations for managing hyperlipidaemia in elderly patients with cardiovascular disease.
- To evaluate the applicability of existing data from younger populations and middle-aged men to elderly individuals.
- To discuss the implications of treatment decisions on this unique patient group.
Summary:
- Raised cholesterol remains a significant risk factor for coronary heart disease (CHD) in the elderly, with absolute risk increasing despite diminishing relative risk with age.
- Major outcome studies suggest 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) offer benefits to older individuals.
- Current treatment strategies often extrapolate data from younger cohorts and focus on severe hyperlipidaemia cases, particularly in secondary prevention, considering life expectancy.
Impact:
- Highlights the need for tailored therapeutic strategies for elderly patients with hyperlipidaemia.
- Informs clinical practice by emphasizing the extrapolation of data and individualized treatment plans.
- Underscores the economic considerations associated with widespread hyperlipidaemia treatment in the elderly population.
Abstract:
Cardiovascular diseases are frequent in elderly subjects and these patients also frequently present with hyperlipidaemia. Therapy must take current uncertainties into account and, in the absence of therapeutic studies carried out in the elderly, is typically based on a case-by-case approach. Raised cholesterol levels remain a significant risk factor for coronary heart disease (CHD) in the elderly. Although the relative risk of CHD tends to diminish with increasing age, this reduction is accompanied by an increase in absolute risk (i.e. the number of events) as the frequency of the illness increases markedly with age. The results of major outcome studies with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), when analysed according to patient age, indicate that the benefits of these agents are not merely confined to younger individuals. However, the elderly form a unique patient population: the proportion of women is greater and the profile of cardiovascular illnesses is characterized, among other things, by a greater incidence of cerebrovascular accidents. Moreover, the potential widespread treatment of hyperlipidaemia in the elderly has profound economic implications. Under these circumstances, the clinical practice recommendations depend upon a reasonable extrapolation of epidemiological and therapeutic data obtained from middle-aged men. At present, treatment is therefore aimed at patients with the most severe forms of hyperlipidaemia, generally in the secondary prevention setting, taking into account the patient's life expectancy.